

# Gisela M Vaitaitis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/676376/publications.pdf>

Version: 2024-02-01

21  
papers

578  
citations

623734

14  
h-index

888059

17  
g-index

21  
all docs

21  
docs citations

21  
times ranked

426  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3782-3787.	7.1	101
2	Cutting Edge: CD40-Induced Expression of Recombination Activating Gene (RAG) 1 and RAG2: A Mechanism for the Generation of Autoaggressive T Cells in the Periphery. Journal of Immunology, 2003, 170, 3455-3459.	0.8	58
3	Peripheral CD40 <sup>+</sup> auto-aggressive T cell expansion during insulin-dependent diabetes mellitus. European Journal of Immunology, 2004, 34, 1488-1497.	2.9	56
4	A unique T cell subset described as CD40 <sup>+</sup> T cells (TCD40) in human type 1 diabetes. Clinical Immunology, 2007, 124, 138-148.	3.2	55
5	Galectin-9 Controls CD40 Signaling through a Tim-3 Independent Mechanism and Redirects the Cytokine Profile of Pathogenic T Cells in Autoimmunity. PLoS ONE, 2012, 7, e38708.	2.5	51
6	Disruption of the homeostatic balance between autoaggressive (CD4 <sup>+</sup> CD40 <sup>+</sup> ) and regulatory (CD4 <sup>+</sup> ) T cells in type 1 diabetes. Journal of Immunology, 2013, 191, 4100-4108.	3.3	41
7	A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia, 2014, 57, 2366-2373.	6.3	35
8	High Distribution of CD40 and TRAF2 in Th40 T Cell Rafts Leads to Preferential Survival of this Auto-Aggressive Population in Autoimmunity. PLoS ONE, 2008, 3, e2076.	2.5	32
9	CD40-mediated signalling influences trafficking, T cell receptor expression, and T cell pathogenesis, in the NOD model of type 1 diabetes. Immunology, 2017, 152, 243-254.	4.4	25
10	Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. Journal of Neuroimmunology, 2014, 270, 75-85.	2.3	24
11	CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity. Molecular Immunology, 2010, 47, 2303-2313.	2.2	22
12	The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells. Current Immunology Reviews, 2010, 6, 130-136.	1.2	20
13	CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression. Cellular and Molecular Immunology, 2013, 10, 483-489.	10.5	19
14	Th40 cells (CD4 <sup>+</sup> CD40 <sup>+</sup> T cells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells. PLoS ONE, 2017, 12, e0172037.	2.5	19
15	A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2019, 332, 8-15.	2.3	9
16	Biomarker Discovery in Pre-Type 1 Diabetes; Th40 Cells as a Predictive Risk Factor. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4127-4142.	3.6	8
17	CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter]. Diabetologia, 2019, 62, 1730-1731.	6.3	3
18	CD5, CD28 and CD40 as interconnected costimulatory/immune modulators of T cells responses in the NOD, NOR and BALB mouse strains. FASEB Journal, 2008, 22, 663.15.	0.5	0

#	ARTICLE	IF	CITATIONS
19	TCR Revision As A Mechanism Of Peripheral Tolerance. FASEB Journal, 2008, 22, 669.22.	0.5	0
20	Are we aiming to miss in translational autoimmunity treatments?. F1000Research, 2018, 7, 1754.	1.6	0
21	Are we aiming to miss in translational autoimmunity treatments?. F1000Research, 2018, 7, 1754.	1.6	0